Ben Field

Dr Ben Field


Clinical Reader in Diabetes and Endocrinology
BMedSci MBBS MSc PGCertULT PhD FRCP

About

University roles and responsibilities

  • Caldicott Guardian

    Publications

    Ruan Y, Ryder REJ, De P, Field BCT, Narendran P, Iqbal A, Gandhi R, Harris S, Nagi D, Aziz U, Karra E, Ghosh S, Hanif W, Edwards AE, Zafar M, Dashora U, Várnai KA, Davies J, Wild SH, Wilmot EG, Webb D, Khunti K, Rea R, ABCD Covid-19 Audit Group (2021) A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. Diabetologia 2021; 64: 1717–24
    Rodway A, Stafford M, Wilding S, Ntagiantas N, Patsiogiannis V, Allan C, Field B, Clark J, Casal FP, Pankhania A, Loosemore T, Heiss C (2021) Day case angioplasty in a secondary care setting - initial experience. Vasa. 2021; 50(3): 202-8.
    Hinton W, Nemeth B, de Lusignan S, Field B, Feher MD, Munro N, Roberts LN, Arya R, Whyte MB (2021) Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism. Diabet Med 2021; 38: e14452.
    Tan TM, Salem V, Troke RC, Alsafi A, Field BCT, De Silva A, Misra S, Baynes KCR, Donaldson M, Minnion J, Ghatei MA, Godsland IF, Bloom SR (2014) Combination of peptide YY3-36 with GLP-17-36 amide causes an increase in first-phase insulin secretion after IV glucose. J Clin Endocrinol Metab 2014; 99(11): E2317-24
    Tan TM*, Field BCT*, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Maffe J, Baynes KCR, De Silva A, Viardot A, Alsafi A, Frost GS, Ghatei MA, Bloom SR (2013) Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013; 62(4): 1131-8 (*joint first author)
    Salem V, Hopkins TG, El-Gayar H, Zac-Varghese S, Goldstone AP, Todd JF, Dhillo W, Field BCT, Martin N, Hatfield E, Donaldson M, Palazzo F, Meeran K, Jackson J, Tan T (2012) Adrenal venous sampling as a diagnostic procedure for primary hyperaldosteronism: experience from a tertiary referral centre. Hormones 2012; 11(2): 151-9
    Tan TM*, Field BCT*, Minnion JS, Cuenco-Shillito J, Chambers ES, Zac-Varghese S, Brindley CJ, Mt-Isa S, Fiorentino F, Ashby D, Ward I, Ghatei MA, Bloom SR (2012) Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol 2012; 73(2): 232-9 (*joint first author)
    Addison ML, Minnion JS, Shillito JC, Suzuki K, Tan TM, Field BCT, Germain-Zito N, Ghatei MA, Bloom SR, Murphy KG (2011) A role for metalloendopeptidases in the breakdown of the gut hormone, PYY3–36. Endocrinology 2011; 152(12): 4630-40
    Sharma S, Radomska-Botelho Moniz A, Triantis I, Michelakis K, Trzebinski J, Azarbadegan A, Field B, Toumazou C, Eames I, Cass A (2011) An integrated silicon sensor with microfluidic chip for monitoring potassium and pH. Microfluid Nanofluid 2011; 10(5): 1119-25
    Liu Y-L, Ford H, Druce MR, Minnion JS, Field BCT, Cuenco-Shillito J, Baxter J, Murphy KG, Ghatei MA, Bloom SR (2010) Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Int J Obes 2010; 34(12): 1715-25
    Field BCT*, Wren AM*, Peters V, Baynes KCR, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR (2010) PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59(7): 1635-9 (*joint first author)
    Druce MR, Minnion JS, Field BCT, Patel SR, Cuenco J, Tilby M, Murphy KG, Ghatei MA, Bloom SR (2009) Investigation of structure-activity relationships of oxyntomodulin using oxyntomodulin analogues. Endocrinology 2009; 150(4): 1712-21
    Feather A, Field BCT, Lumley JSP & Visvanathan R (2007) Medical Finals: Short cases with structured answers, 2nd edition. Pastest, Knutsford, 2007
    Feather A, Domizio P, Field BCT, Knowles, CH, Lumley JSP (2008) EMQs for medical students, Vols 1 & 2, 1st edition. Pastest, Knutsford, 2001, and 2nd edition 2008